Hikma Pharmaceuticals H2 Earnings Call Highlights

Management acknowledged challenges for the Injectables business in 2025 and 2026. Deputy CEO North America and Europe Khalid Nabilsi cited reduced CMO contribution as a key issue, noting that one major customer is shifting some manufacturing to domestic U.S. production—capacity Hikma said it cannot fully offer until the Bedford facility is ramped and commercialized in 2028. Nabilsi also pointed to delayed product launches and lower optimism around a small biosimilar component, including liraglutide.He descr ...